Electrostatic Surface Potential as a Key Parameter in Virus Transmission and Evolution: How to Manage Future Virus Pandemics in the Post-COVID-19 Era

Virus-cell interactions involve fundamental parameters that need to be considered in strategies implemented to control viral outbreaks. Among these, the surface electrostatic potential can give valuable information to deal with new epidemics. In this article, we describe the role of this key parameter in the hemagglutination of red blood cells and in the co-evolution of synaptic receptors and neurotransmitters. We then establish the functional link between lipid rafts and the electrostatic potential of viruses, with special emphasis on gangliosides, which are sialic-acid-containing, electronegatively charged plasma membrane components. We describe the common features of ganglioside binding domains, which include a wide variety of structures with little sequence homology but that possess key amino acids controlling ganglioside recognition. We analyze the role of the electrostatic potential in the transmission and intra-individual evolution of HIV-1 infections, including gatekeeper and co-receptor switch mechanisms. We show how to organize the epidemic surveillance of influenza viruses by focusing on mutations affecting the hemagglutinin surface potential. We demonstrate that the electrostatic surface potential, by modulating spike-ganglioside interactions, controls the hemagglutination properties of coronaviruses (SARS-CoV-1, MERS-CoV, and SARS-CoV-2) as well as the structural dynamics of SARS-CoV-2 evolution. We relate the broad-spectrum antiviral activity of repositioned molecules to their ability to disrupt virus-raft interactions, challenging the old concept that an antibiotic or anti-parasitic cannot also be an antiviral. We propose a new concept based on the analysis of the electrostatic surface potential to develop, in real time, therapeutic and vaccine strategies adapted to each new viral epidemic.

[1]  C. Mukhopadhyay,et al.  Identification of possible binding modes of SARS-CoV-2 spike N-terminal domain for ganglioside GM1 , 2022, Chemical Physics Letters.

[2]  B. Scola,et al.  SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects , 2022, bioRxiv.

[3]  J. Fantini,et al.  A Vaccine Strategy Based on the Identification of an Annular Ganglioside Binding Motif in Monkeypox Virus Protein E8L , 2022, Viruses.

[4]  J. Fantini,et al.  The Epigenetic Dimension of Protein Structure Is an Intrinsic Weakness of the AlphaFold Program , 2022, Biomolecules.

[5]  Mujahed I. Mustafa,et al.  Novel multi epitope-based vaccine against monkeypox virus: vaccinomic approach , 2022, Scientific Reports.

[6]  J. Tomaskova,et al.  Cellular Lipids—Hijacked Victims of Viruses , 2022, Viruses.

[7]  A. Baj,et al.  Monkeypox: An international epidemic , 2022, Reviews in medical virology.

[8]  M. Koopmans,et al.  Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct , 2022, Science Immunology.

[9]  Michael M. Desai,et al.  Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1 , 2022, bioRxiv.

[10]  J. Fantini,et al.  Structural Dynamics of the SARS-CoV-2 Spike Protein: A 2-Year Retrospective Analysis of SARS-CoV-2 Variants (from Alpha to Omicron) Reveals an Early Divergence between Conserved and Variable Epitopes , 2022, Molecules.

[11]  M. Haddadi,et al.  Antiviral effects of azithromycin: A narrative review , 2022, Biomedicine & Pharmacotherapy.

[12]  B. La Scola,et al.  The puzzling mutational landscape of the SARS‐2‐variant Omicron , 2022, Journal of medical virology.

[13]  Catherine Z. Chen,et al.  A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry , 2022, SLAS Discovery.

[14]  Jie-Li Hu,et al.  Increased immune escape of the new SARS-CoV-2 variant of concern Omicron , 2021, Cellular & Molecular Immunology.

[15]  J. Fantini,et al.  Ganglioside binding domains in proteins: Physiological and pathological mechanisms. , 2022, Advances in protein chemistry and structural biology.

[16]  S. Pascarella,et al.  The electrostatic potential of the Omicron variant spike is higher than in Delta and Delta‐plus variants: A hint to higher transmissibility? , 2021, Journal of medical virology.

[17]  J. Diallo,et al.  Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern , 2021, ACS infectious diseases.

[18]  Catherine Z. Chen,et al.  A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry , 2021, bioRxiv.

[19]  V. Pravica,et al.  Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? , 2021, Viruses.

[20]  J. Fantini,et al.  Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks , 2021, Journal of Infection.

[21]  William T. Harvey,et al.  SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.

[22]  G. Barton,et al.  Effects of common mutations in the SARS-CoV-2 Spike RBD domain and its ligand the human ACE2 receptor on binding affinity and kinetics , 2021, bioRxiv.

[23]  Md. Mujibur Rahman,et al.  Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial , 2021, The Journal of international medical research.

[24]  Xue-Long Sun The role of cell surface sialic acids for SARS-CoV-2 infection , 2021, Glycobiology.

[25]  A. Cook,et al.  Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial , 2021, International Journal of Infectious Diseases.

[26]  M. Beltramello,et al.  N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 , 2021, Cell.

[27]  L. Bao,et al.  Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2 , 2021, Acta Pharmaceutica Sinica B.

[28]  J. López-Guerrero,et al.  Membrane Rafts: Portals for Viral Entry , 2021, Frontiers in Microbiology.

[29]  A. Javadi,et al.  Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial , 2020, Asian Pacific Journal of Tropical Medicine.

[30]  M. Taha,et al.  Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2 , 2020, Cells.

[31]  F. X. Qin,et al.  Direct inhibitory effect on viral entry of influenza A and SARS‐CoV‐2 viruses by azithromycin , 2020, Cell proliferation.

[32]  J. Fantini,et al.  Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19 , 2020, Biochemical and Biophysical Research Communications.

[33]  D. Jans,et al.  Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? , 2020, Cells.

[34]  M. Saviano,et al.  A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment , 2020, Frontiers in Molecular Biosciences.

[35]  Francesco Filippini,et al.  Normal modes analysis and surface electrostatics of haemagglutinin proteins as fingerprints for high pathogenic type A influenza viruses , 2020, BMC Bioinformatics.

[36]  M. Farzan,et al.  Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 , 2020, bioRxiv.

[37]  J. Sodroski,et al.  Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike , 2020, Nature.

[38]  G. Melino,et al.  Is hydroxychloroquine beneficial for COVID-19 patients? , 2020, Cell Death & Disease.

[39]  J. Fantini,et al.  Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of Aβ oligomers? , 2020, Protein science : a publication of the Protein Society.

[40]  Emanuele Rizzo Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action , 2020, Naunyn-Schmiedeberg's Archives of Pharmacology.

[41]  S. D. Fernando,et al.  Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review , 2020, Clinical Microbiology and Infection.

[42]  J. Fantini,et al.  Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal , 2020, International Journal of Antimicrobial Agents.

[43]  D. Raoult,et al.  In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect , 2020, Microbial Pathogenesis.

[44]  Jacques Fantini,et al.  Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection , 2020, International Journal of Antimicrobial Agents.

[45]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[46]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[47]  J. Küpper,et al.  Variations in Proteins Dielectric Constants , 2020, ChemistryOpen.

[48]  T. Geijtenbeek,et al.  Negative and Positive Selection Pressure During Sexual Transmission of Transmitted Founder HIV-1 , 2019, Front. Immunol..

[49]  M. J. Robertson,et al.  Structural Insights into Metabotropic Glutamate Receptor Activation , 2018, Nature.

[50]  J. McFadden,et al.  The origins of quantum biology , 2018, Proceedings of the Royal Society A.

[51]  M. Maginnis Virus–Receptor Interactions: The Key to Cellular Invasion , 2018, Journal of Molecular Biology.

[52]  G. Ayora-Talavera Sialic acid receptors: focus on their role in influenza infection , 2018 .

[53]  F. Filippini,et al.  Electrostatic Variation of Haemagglutinin as a Hallmark of the Evolution of Avian Influenza Viruses , 2018, Scientific Reports.

[54]  Oh,et al.  Sialic acid receptors: focus on their role in influenza infection , 2018 .

[55]  M. Tortorici,et al.  Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein , 2017, Proceedings of the National Academy of Sciences.

[56]  V. Lee,et al.  Polysulfonate suramin inhibits Zika virus infection , 2017, Antiviral research.

[57]  B. Schnierle,et al.  Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry , 2016, Virology Journal.

[58]  R. Schnaar Gangliosides of the Vertebrate Nervous System. , 2016, Journal of molecular biology.

[59]  D. Raoult,et al.  Fighting viruses with antibiotics: an overlooked path , 2016, International Journal of Antimicrobial Agents.

[60]  G. Simmons,et al.  Pseudotyping Viral Vectors With Emerging Virus Envelope Proteins. , 2016, Current gene therapy.

[61]  Aiping Wu,et al.  Antigenic Patterns and Evolution of the Human Influenza A (H1N1) Virus , 2015, Scientific Reports.

[62]  Johannes E. Schindelin,et al.  The ImageJ ecosystem: An open platform for biomedical image analysis , 2015, Molecular reproduction and development.

[63]  J. Fantini,et al.  Brain Lipids in Synaptic Function and Neurological Disease: Clues to Innovative Therapeutic Strategies for Brain Disorders , 2015 .

[64]  F. Filippini,et al.  Comparative structural analysis of haemagglutinin proteins from type A influenza viruses: conserved and variable features , 2014, BMC Bioinformatics.

[65]  T. Stehle,et al.  The sweet spot: defining virus–sialic acid interactions , 2014, Nature Reviews Microbiology.

[66]  Rita Gerardy-Schahn,et al.  Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. , 2014, Physiological reviews.

[67]  Thomas Lengauer,et al.  Modelling binding between CCR5 and CXCR4 receptors and their ligands suggests the surface electrostatic potential of the co-receptor to be a key player in the HIV-1 tropism , 2013, Retrovirology.

[68]  J. Castelán-Vega,et al.  Analysis of Adaptation Mutants in the Hemagglutinin of the Influenza A(H1N1)pdm09 Virus , 2013, PloS one.

[69]  Yoshihiro Kawaoka,et al.  Receptor binding by a ferret-transmissible H5 avian influenza virus , 2013, Nature.

[70]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[71]  D. Stallknecht,et al.  Expression and distribution of sialic acid influenza virus receptors in wild birds , 2013, Avian pathology : journal of the W.V.P.A.

[72]  P. Lio’,et al.  The Puzzling Role of CXCR4 in Human Immunodeficiency Virus Infection , 2013, Theranostics.

[73]  Ryan McBride,et al.  Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities , 2013, Proceedings of the National Academy of Sciences.

[74]  Chun-ching Lin,et al.  Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry , 2013, BMC Microbiology.

[75]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[76]  J. Fantini,et al.  Selective transmigration of monocyte-associated HIV-1 across a human cervical monolayer and its modulation by seminal plasma , 2012, AIDS.

[77]  Chris A Kieslich,et al.  Clustering of HIV-1 Subtypes Based on gp120 V3 Loop electrostatic properties , 2012, BMC biophysics.

[78]  Alexander D. MacKerell,et al.  Glycan reader: Automated sugar identification and simulation preparation for carbohydrates and glycoproteins , 2011, J. Comput. Chem..

[79]  Peter Politzer,et al.  The electrostatic potential: an overview , 2011 .

[80]  J. Grivel,et al.  Selective transmission of R5 HIV-1 variants: where is the gatekeeper? , 2011, Journal of Translational Medicine.

[81]  E. Arts,et al.  Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. , 2011, The Lancet. Infectious diseases.

[82]  R. E. Cunningham,et al.  Role of Sialic Acid Binding Specificity of the 1918 Influenza Virus Hemagglutinin Protein in Virulence and Pathogenesis for Mice , 2009, Journal of Virology.

[83]  H. Garg,et al.  Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry. , 2008, Antiviral research.

[84]  M. Churchill,et al.  Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. , 2008, Virology.

[85]  K. Dimock,et al.  Sialic acid tissue distribution and influenza virus tropism , 2008, Influenza and other respiratory viruses.

[86]  Sunhwan Jo,et al.  PBEQ-Solver for online visualization of electrostatic potential of biomolecules , 2008, Nucleic Acids Res..

[87]  J. Tam,et al.  Lipid rafts are involved in SARS-CoV entry into Vero E6 cells , 2008, Biochemical and Biophysical Research Communications.

[88]  Anne Imberty,et al.  N-Glycolyl GM1 Ganglioside as a Receptor for Simian Virus 40 , 2007, Journal of Virology.

[89]  P. Auffinger,et al.  Nucleic acid solvation: from outside to insight. , 2007, Current opinion in structural biology.

[90]  K. Ikuta,et al.  Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle , 2006, Microbes and Infection.

[91]  Anne Imberty,et al.  N-Glycolyl GM 1 Ganglioside as a Receptor for Simian Virus 40 † , 2007 .

[92]  Martin Chaplin,et al.  Do we underestimate the importance of water in cell biology? , 2006, Nature Reviews Molecular Cell Biology.

[93]  J. Fantini,et al.  Prediction of glycolipid-binding domains from the amino acid sequence of lipid raft-associated proteins: application to HpaA, a protein involved in the adhesion of Helicobacter pylori to gastrointestinal cells. , 2006, Biochemistry.

[94]  Robin Shattock,et al.  Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? , 2006, Nature Reviews Microbiology.

[95]  Carlos L. Cesar,et al.  Red blood cell membrane viscoelasticity, agglutination, and zeta potential measurements with double optical tweezers , 2006, SPIE BiOS.

[96]  S. Huang,et al.  Dimensions of systems biology. , 2006, Reviews of physiology, biochemistry and pharmacology.

[97]  B. Verrier,et al.  Selective sequestration of X4 isolates by human genital epithelial cells: Implication for virus tropism selection process during sexual transmission of HIV , 2005, Journal of medical virology.

[98]  Sebastian Bonhoeffer,et al.  The HIV coreceptor switch: a population dynamical perspective. , 2005, Trends in microbiology.

[99]  J. Rojo,et al.  Glycodendritic structures: promising new antiviral drugs. , 2004, The Journal of antimicrobial chemotherapy.

[100]  A. Lapedes,et al.  Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.

[101]  John P. Moore,et al.  The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. , 2004, AIDS research and human retroviruses.

[102]  R. Weinstein Planning for epidemics--the lessons of SARS. , 2004, The New England journal of medicine.

[103]  A. Benesi,et al.  Synthesis of novel, multivalent glycodendrimers as ligands for HIV-1 gp120. , 2004, Bioconjugate chemistry.

[104]  C. Martínez-A,et al.  Pathogens: raft hijackers , 2003, Nature Reviews Immunology.

[105]  J. Fantini How sphingolipids bind and shape proteins: molecular basis of lipid-protein interactions in lipid shells, rafts and related biomembrane domains , 2003, Cellular and Molecular Life Sciences CMLS.

[106]  L. Pike Lipid rafts Published, JLR Papers in Press, February 1, 2003. DOI 10.1194/jlr.R200021-JLR200 , 2003, Journal of Lipid Research.

[107]  S. Philpott HIV-1 coreceptor usage, transmission, and disease progression. , 2003, Current HIV research.

[108]  J. Fantini,et al.  Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases , 2002, Expert Reviews in Molecular Medicine.

[109]  A. Brigo,et al.  The Poisson–Boltzmann equation for biomolecular electrostatics: a tool for structural biology , 2002, Journal of molecular recognition : JMR.

[110]  J. Fantini,et al.  Identification of a Common Sphingolipid-binding Domain in Alzheimer, Prion, and HIV-1 Proteins* , 2002, The Journal of Biological Chemistry.

[111]  J. Fantini,et al.  Amphiphilic anionic analogues of galactosylceramide: synthesis, anti-HIV-1 activity, and gp120 binding. , 2001, Journal of medicinal chemistry.

[112]  J. Fantini,et al.  Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: how to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale. , 2001, The Journal of infectious diseases.

[113]  Jaap Goudsmit,et al.  N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization* , 2001, The Journal of Biological Chemistry.

[114]  A. Osterhaus,et al.  Macrophage Tropism of Human Immunodeficiency Virus Type 1 Facilitates In Vivo Escape from Cytotoxic T-Lymphocyte Pressure , 2001, Journal of Virology.

[115]  J. Sleasman,et al.  Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). , 2000, AIDS.

[116]  C. Martínez-A,et al.  Membrane raft microdomains mediate lateral assemblies required for HIV‐1 infection , 2000, EMBO reports.

[117]  A M Aubertin,et al.  Synthesis of single- and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles and their anti-HIV-1 activity. , 2000, Carbohydrate research.

[118]  D. Dimitrov,et al.  Glycosphingolipids Promote Entry of a Broad Range of Human Immunodeficiency Virus Type 1 Isolates into Cell Lines Expressing CD4, CXCR4, and/or CCR5 , 2000, Journal of Virology.

[119]  J. Sodroski,et al.  Selective Interactions of Polyanions with Basic Surfaces on Human Immunodeficiency Virus Type 1 gp120 , 2000, Journal of Virology.

[120]  J. Fantini,et al.  Human Erythrocyte Glycosphingolipids as Alternative Cofactors for Human Immunodeficiency Virus Type 1 (HIV-1) Entry: Evidence for CD4-Induced Interactions between HIV-1 gp120 and Reconstituted Membrane Microdomains of Glycosphingolipids (Gb3 and GM3) , 1999, Journal of Virology.

[121]  H. Gelberg,et al.  Structure and Function of a Ganglioside Receptor for Porcine Rotavirus , 1998, Journal of Virology.

[122]  J. Fantini,et al.  Sulfatide inhibits HIV-1 entry into CD4-/CXCR4+ cells. , 1998, Virology.

[123]  W. Im,et al.  Continuum solvation model: Computation of electrostatic forces from numerical solutions to the Poisson-Boltzmann equation , 1998 .

[124]  J. Fantini,et al.  Sequential interaction of CD4 and HIV-1 gp120 with a reconstituted membrane patch of ganglioside GM3: implications for the role of glycolipids as potential HIV-1 fusion cofactors. , 1998, Biochemical and biophysical research communications.

[125]  J. Fantini,et al.  Specific Interaction of HIV-1 and HIV-2 Surface Envelope Glycoproteins with Monolayers of Galactosylceramide and Ganglioside GM3* , 1998, The Journal of Biological Chemistry.

[126]  J. Albert,et al.  Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. , 1998, Virology.

[127]  J. Fantini,et al.  HIV-1 transmission across the vaginal epithelium. , 1997, AIDS.

[128]  A. Trkola,et al.  Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.

[129]  J. Fantini,et al.  Synthetic Soluble Analogs of Galactosylceramide (GalCer) Bind to the V3 Domain of HIV-1 gp120 and Inhibit HIV-1-induced Fusion and Entry* , 1997, The Journal of Biological Chemistry.

[130]  J. Fantini,et al.  SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids. , 1996, Biochemistry.

[131]  B. Honig,et al.  Classical electrostatics in biology and chemistry. , 1995, Science.

[132]  J. Fantini,et al.  SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[133]  M. Wainberg,et al.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection , 1995 .

[134]  J. Fantini,et al.  Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line , 1995, Journal of virology.

[135]  J. Fantini,et al.  Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. , 1994, The Journal of biological chemistry.

[136]  Y. Suzuki,et al.  Gangliosides as influenza virus receptors. Variation of influenza viruses and their recognition of the receptor sialo-sugar chains. , 1994, Progress in lipid research.

[137]  M. Froimowitz,et al.  HyperChem: a software package for computational chemistry and molecular modeling. , 1993, BioTechniques.

[138]  H. Moreau,et al.  Galactosyl ceramide (or a closely related molecule) is the receptor for human immunodeficiency virus type 1 on human colon epithelial HT29 cells , 1992, Journal of virology.

[139]  D. Silberberg,et al.  Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. , 1991, Science.

[140]  Barry Honig,et al.  Calculating total electrostatic energies with the nonlinear Poisson-Boltzmann equation , 1990 .

[141]  K. Gustafson,et al.  AIDS-antiviral sulfolipids from cyanobacteria (blue-green algae). , 1989, Journal of the National Cancer Institute.

[142]  E. De Clercq,et al.  Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus , 1988, Antimicrobial Agents and Chemotherapy.

[143]  S. Cusack,et al.  Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid , 1988, Nature.

[144]  C. J. Oss,et al.  Hemagglutination and the Closest Distance of Approach of Normal, Neuraminidase‐ and Papain‐Treated Erythrocytes , 1984, Vox sanguinis.

[145]  J M Blaney,et al.  Electrostatic potential molecular surfaces. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[146]  J. Paulson,et al.  Specific gangliosides function as host cell receptors for Sendai virus. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[147]  D. Wolf,et al.  Composition and functioin of human cervical mucus. , 1980, Biochimica et biophysica acta.

[148]  W. Brodsky Protein synthesis rhythm. , 1975 .

[149]  P Sturgeon,et al.  Effects of Proteases and Neuraminidase on RBC Surface Charge and Agglutination , 1975, Vox sanguinis.